Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
18.86
-0.13 (-0.68%)
Aug 10, 2026, 4:00 PM EDT - Market closed
AAPG Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,470 | 1,261 | 1,094 | 1,492 | 1,744 |
Cash & Short-Term Investments | 2,470 | 1,261 | 1,094 | 1,492 | 1,744 |
Cash Growth | 95.85% | 15.30% | -26.70% | -14.43% | 70.23% |
Accounts Receivable | 252.94 | 83.14 | 145.89 | 54.36 | 53.97 |
Inventory | 28.62 | 6.6 | 16.17 | 9.45 | 3.93 |
Other Current Assets | 192.53 | 123.21 | 88.29 | 80.44 | 83.56 |
Total Current Assets | 2,944 | 1,474 | 1,344 | 1,636 | 1,885 |
Net Property, Plant & Equipment | 829.06 | 905.56 | 957.07 | 648.72 | 844.37 |
Other Intangible Assets | 65.94 | 76 | 85.45 | 84.3 | 60.41 |
Goodwill | 24.69 | 24.69 | 24.69 | 24.69 | 24.69 |
Long-Term Investments | 37.03 | 33.86 | 18.95 | 18.53 | 27.85 |
Other Long-Term Assets | 62.68 | 103.54 | 70.06 | 417.52 | 97.46 |
Total Assets | 3,964 | 2,618 | 2,500 | 2,830 | 2,940 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 106.74 | 91.97 | 72.45 | 95.56 | 70.86 |
Accrued Expenses | 276.67 | 258.1 | 206.91 | 240.03 | 194.18 |
Current Portion of Long-Term Debt | 1,222 | 779.06 | 616.4 | 518.38 | 49.45 |
Unearned Revenue | 37.49 | 37.49 | 38.41 | 24.35 | 24.36 |
Other Current Liabilities | - | - | - | 2.82 | 22.26 |
Total Current Liabilities | 1,643 | 1,167 | 934.17 | 881.15 | 361.11 |
Long-Term Debt | 757.24 | 889.44 | 1,179 | 1,274 | 1,035 |
Other Long-Term Liabilities | 228.76 | 287.6 | 316.4 | 266.11 | 309.38 |
Total Long-Term Liabilities | 985.99 | 1,177 | 1,496 | 1,540 | 1,344 |
Total Liabilities | 2,629 | 2,344 | 2,430 | 2,422 | 1,705 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.26 | 0.21 | 0.2 | 0.18 | 0.18 |
Treasury Stock | -2.96 | -0.01 | -21.35 | -26.55 | -0 |
Additional Paid-in Capital | 8,520 | 6,161 | 5,580 | 435.03 | 1,235 |
Accumulated Other Comprehensive Income | -179.09 | -126.07 | -133.02 | - | - |
Retained Earnings | -7,013 | -5,771 | -5,365 | - | - |
Total Common Shareholders' Equity | 1,324 | 264.19 | 60.42 | 408.66 | 1,235 |
Minority Interest | 9.75 | 9.97 | 10.22 | - | - |
Shareholders' Equity | 1,334 | 274.16 | 70.63 | 408.66 | 1,235 |
Total Liabilities & Equity | 3,964 | 2,618 | 2,500 | 2,830 | 2,940 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,980 | 1,668 | 1,796 | 1,793 | 1,084 |
Net Cash (Debt) | 490.37 | -407.29 | -701.76 | -300.49 | 659.53 |
Net Cash Growth | - | - | - | - | 33.32% |
Net Cash Per Share | 5.51 | -5.39 | -9.94 | -4.56 | 10.36 |
Book Value | 1,324 | 264.19 | 60.42 | 408.66 | 1,235 |
Book Value Per Share | 14.88 | 3.50 | 0.86 | 6.20 | 19.40 |
Tangible Book Value | 1,234 | 163.5 | -49.72 | 299.66 | 1,150 |
Tangible Book Value Per Share | 13.86 | 2.17 | -0.70 | 4.55 | 18.06 |